GC101 TIL Therapy Achieves Complete Response in Lung Cancer Patient Within Just 12 Weeks: World’s First Lymphodepletion-Free Autologous TIL Treatment Emerges as a Game-Changer

In April 2022, Mr. Zhang discovered a gradually worsening pain in his left chest and went to the hospital for detailed examinations, where he was diagnosed withLung AdenocarcinomaStage ⅣB, worse still, genetic testing revealed the presence ofKRAS G12D mutation, a genetic abnormality with extremely high malignancy, still lacks targeted drugs approved for marketing globally.

In order to control the condition as soon as possible, Mr. Zhang receivedThe combination of immunotherapy and chemotherapy, as well as the combination of immunotherapy, anti-angiogenic inhibitors, and chemotherapy, unfortunately, eventuallyAll discontinued the medication due to disease progression or intolerance, and currently, there are no better treatment options available in clinical practice.His condition is still progressing rapidly.

Fortunately, a well-known cancer center in China is currently conducting a new type of cellular immunotherapy--GC101 TILThe clinical trial, in September 2024, Mr. Zhang successfully enrolled in this study.

GC101 TIL Cell Therapy, developed by Juncell Therapeutics using the DeepTIL® cell expansion platform, can cultivate a sufficient number of highly active TIL cells without high concentrations of IL-2 and feeder cells, and it is not dependent on IL-2.In clinical applications, GC101 eliminates the need for lymphodepletion and any dose of IL-2 injection, effectively addressing the clinical challenges associated with conventional TIL therapy, which relies on high-dose chemotherapy for lymphodepletion and high-dose IL-2 injections.

Doctors isolated immune cells known as tumor-infiltrating lymphocytes (TILs) from the tumor surgically removed from Mr. Zhang. These immune cells are like a "dare-to-die squad" that infiltrates enemy lines to engage in close combat with cancer cells, possessing the strongest recognition and killing abilities. By culturing and expanding these rare but extremely valuable immune cells in the laboratory, billions of TILs with enhanced combat power and vastly increased numbers can be obtained. Once infused back into the patient’s body, these cells will continue to seek out and destroy cancer cells.As time goes by, this"Live" Cell TherapySustainably effective, when cancer cells reappear in the body, these immune cells can quickly launch an attack.

Surprising changes began to appear after receiving GC101 TIL treatment. During the treatment process, apart from transient hematological toxicity during the preconditioning phase, no other adverse reactions occurred.

At the 6th week after treatment, a miracle began to appear: the tumor shrank by 45%, tumor markers returned to normal, cancer pain was alleviated, and cervical lymph nodes disappeared.

By the 12th week, the large tumor target lesions had completely disappeared, achieving a complete response (CR). At 18 weeks, the CR status was still ongoing. This means that with just a single dose, GC101 TIL can continuously exert its tumor-killing effects, leaving no place for cancer cells to hide.

As the tumor disappeared, Mr. Zhang's life underwent an earth-shaking transformation. His health condition continued to improve, thanks to the long-lasting effects of TIL therapy, which eliminated the need for frequent hospital visits for additional treatments. Regular follow-ups at the hospital no longer required assistance from family members. In daily life, he was fully capable of taking care of himself, returning to a normal family life and enjoying every moment spent with his loved ones.